Surgery to remove as much tumour as possible in advanced pancreatic neuroendocrine tumours
Tests debulking surgery in adults whose pancreatic neuroendocrine tumour has spread.
Plain-language title generated from the registry record
Registry title: Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not
Key facts
- Where
- Gothenburg, Lund, Stockholm, and Uppsala, SwedenSee the 4 sites
Where in Sweden
- Sahlgrenska University HospitalGothenburg, SwedenTaking people
- Skåne University HospitalLund, SwedenNot yet recruiting
- Karolinska University HospitalStockholm, SwedenTaking people
- Uppsala University HospitalUppsala, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Uppsala University
- Trial code
- NCT07273409
- Record updated
- 22 January 2026
- Original description
Pancreatic neuroendocrine tumours (pan-NETs) are neoplasms arising from the endocrine cells of the pancreas. Although pan-NET are quite rare, the incidence is on the rise and together with other abdominal neuroendocrine tumours an approximate incidence in Sweden would be 850 patients per year extrapolating from Norwegian data. Pan-NET are divided into symptomatic hormone producing tumours (such as insulinomas/glucagonomas/VIPomas) or non-functioning tumours that often are asymptomatic. As early symptoms often are lacking in non-functioning-pan-NET, many patients present with distant metastases and are thus beyond a curative surgical approach at the time of diagnosis. Metastatic non-functioning pan-NETs present a significant challenge and the optimal management remains a subject of debate.Read full original descriptionShow less
PANcreatic Neuroendocrine Tumour - Optimal Surgical Debulking Or Not (PANTODON). A Prospective, Two Armed, Parallel, Randomised, Controlled International Multicentre Study on WHO Grade 1-2, Stage 4 Pancreatic NET
Pancreatic neuroendocrine tumours (pan-NETs) are neoplasms arising from the endocrine cells of the pancreas. Although pan-NET are quite rare, the incidence is on the rise and together with other abdominal neuroendocrine tumours an approximate incidence in Sweden would be 850 patients per year extrapolating from Norwegian data. Pan-NET are divided into symptomatic hormone producing tumours (such as insulinomas/glucagonomas/VIPomas) or non-functioning tumours that often are asymptomatic. As early symptoms often are lacking in non-functioning-pan-NET, many patients present with distant metastases and are thus beyond a curative surgical approach at the time of diagnosis. Metastatic non-functioning pan-NETs present a significant challenge and the optimal management remains a subject of debate.
This is a prospective, two armed, parallel, randomised, controlled, international multi-centre study, aiming to investigate if a near-total tumour debulking (intervention) in metastatic (stage 4) GI-WHO grade 1-2 pan- NET, with or without oncologic treatment, is superior to oncologic treatment alone (control), with regards to overall survival, health-related quality of life, participant performance status, time until hospitalisation, adverse event characteristics and cost in the short and long term.
Inclusion: Pan- NET, ENETS/AJCC stage 4 determined by CT or PET/CT; Primary tumour or metastases confirmed as Pancreatic NET GI-WHO grade 1-2 pan-NET by histology or cytology; Age ≥ 18 years; Written informed consent obtained.
Exclusion: Risk of surgery deemed too high by MDT or Surgeon (reason to be specified); Previous surgery for pan-NET; Hormonal symptoms caused by a functional pan-NET, not controllable by medical therapy, indicating debulking surgery; Previously included in the current study; The study subject does not fit into either STRATA: a) STRATUM 1: Less than 70% of the total tumour volume can be debulked, b) STRATUM 2: no FDG-PET avid disease is observed OR all (100%) FDG-PET avid tumour is not resectable; Subject not fit for surgery due to comorbidity or advanced age (reason to be specified); Pregnancy; Other reason in the opinion of the Principal Investigator (reason to be specified).